[伴有obinutuzumab输注相关的无动脉粥样硬化证据的心内膜下损伤]
[Subendocardial injury with no evidence of atherosclerosis associated with obinutuzumab infusion].
作者信息
Santarelli Ignacio M, Ibaceta Alaniz Eduardo A, Cabo Constanza P, Guarino Bruno, Cordini Gregorio, Fernández Sofía I, Melero Marcelo J
机构信息
Departamento de Medicina, Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, Argentina. E-mail:
División de Cardiología, Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, Argentina.
出版信息
Medicina (B Aires). 2021;81(6):1052-1055.
Obinutuzumab is a fully humanized monoclonal antibody against CD20 used in the treatment of chronic lymphocytic leukemia. Fatal cardiovascular events have been described, but only in patients with known cardiovascular records. We report the case of an adult male with a high-risk chronic lymphocytic leukemia who developed subendocardial injury, with no evidence of coronary atherosclerosis, during the first administration of obinutuzumab.
奥滨尤妥珠单抗是一种用于治疗慢性淋巴细胞白血病的全人源化抗CD20单克隆抗体。曾有致命心血管事件的报道，但仅见于有已知心血管病史的患者。我们报告一例高危慢性淋巴细胞白血病成年男性患者，在首次使用奥滨尤妥珠单抗期间发生心内膜下损伤，且无冠状动脉粥样硬化证据。
Zotero 插件